Journal
PHARMACOLOGY & THERAPEUTICS
Volume 164, Issue -, Pages 97-104Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2016.04.003
Keywords
Dendritic cell; Tumor immunology; Immunosuppression; Emergency myelopoiesis; Tumor microenvironment
Categories
Funding
- The Jayne Koskinas
- Ted Giovanis Breast Cancer Research Consortium at Wistar
- Ovarian Cancer Research Fund (OCRF) Program Project Development awards
- Irvington Institute Fellowship Program of the Cancer Research Institute
- [R01CA157664]
- [R01CA124515]
- [R01CA178687]
- [P30CA10815]
Ask authors/readers for more resources
Dendritic cells (DCs) with robust immunosuppressive activity are commonly found in the microenvironment of advanced solid tumors. These innate immune cells are generically termed regulatory DCs and include various subsets such as plasmacytoid, conventional and monocyte-derived/inflammatory populations whose normal function is subverted by tumor-derived signals. This review summarizes recent findings on the nature and function of regulatory DCs, their relationship with other myeloid subsets and unique therapeutic opportunities to abrogate malignant progression through their targeting. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available